BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36199139)

  • 1. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
    Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
    BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
    Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
    Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.
    Ørbo HS; Bjørlykke KH; Sexton J; Jyssum I; Tveter AT; Christensen IE; Mjaaland S; Kvien TK; Grødeland G; Kro GB; Jahnsen J; Haavardsholm EA; Munthe LA; Provan SA; Vaage JT; Goll GL; Jørgensen KK; Syversen SW
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38599653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients.
    Picchianti-Diamanti A; Aiello A; Laganà B; Agrati C; Castilletti C; Meschi S; Farroni C; Lapa D; Najafi Fard S; Cuzzi G; Cimini E; Grassi G; Vanini V; Di Rosa R; Salemi S; Nalli G; Salmi A; Repele F; Altera AMG; Maffongelli G; Palazzolo C; Vita S; Leone S; Puro V; Capobianchi MR; Ippolito G; Nicastri E; Goletti D
    Front Immunol; 2021; 12():740249. PubMed ID: 34594343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
    Jørgensen KK; Høivik ML; Chopra A; Benth JŠ; Ricanek P; Moum PB; Jyssum I; Bolstad N; Warren DJ; Vaage PJT; Munthe PLA; Lundin PKEA; Anisdahl K; Syversen SW; Goll GL; Lund-Johansen F; Medhus AW; Jahnsen PJ
    Scand J Gastroenterol; 2023; 58(8):874-882. PubMed ID: 36788656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients.
    Laham G; Martínez AP; Rojas Gimenez W; Amaya L; Abib A; Echegoyen N; Díaz C; Lucero A; Martelli A; Videla C; Neukam K; Di Lello FA
    J Nephrol; 2023 Apr; 36(3):861-872. PubMed ID: 36152219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
    Jyssum I; Kared H; Tran TT; Tveter AT; Provan SA; Sexton J; Jørgensen KK; Jahnsen J; Kro GB; Warren DJ; Vaage EB; Kvien TK; Nissen-Meyer LH; Anderson AM; Grødeland G; Haavardsholm EA; Vaage JT; Mjaaland S; Syversen SW; Lund-Johansen F; Munthe LA; Goll GL
    Lancet Rheumatol; 2022 Mar; 4(3):e177-e187. PubMed ID: 34977602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
    Kennedy NA; Janjua M; Chanchlani N; Lin S; Bewshea C; Nice R; McDonald TJ; Auckland C; Harries LW; Davies M; Michell S; Kok KB; Lamb CA; Smith PJ; Hart AL; Pollok RC; Lees CW; Boyton RJ; Altmann DM; Sebastian S; Powell N; Goodhand JR; Ahmad T
    Gut; 2023 Feb; 72(2):295-305. PubMed ID: 35902214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-spike antibody durability after SARS-CoV-2 vaccination in adolescent solid organ transplant recipients.
    McAteer J; Kalluri DD; Abedon RR; Qin CX; Auerbach SR; Charnaya O; Danziger-Isakov LA; Ebel NH; Feldman AG; Hsu EK; Mohammad S; Perito ER; Thomas AM; Chiang TPY; Garonzik-Wang JM; Segev DL; Werbel WA; Mogul DB
    Pediatr Transplant; 2024 Feb; 28(1):e14671. PubMed ID: 38317335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination.
    Keeshan A; Galipeau Y; Heiskanen A; Collins E; McCluskie PS; Arnold C; Saginur R; Booth R; Little J; McGuinty M; Buchan CA; Crawley A; Langlois MA; Cooper C
    BMJ Open; 2023 Oct; 13(10):e077714. PubMed ID: 37907304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases.
    Oliosi E; Flahault A; Charre C; Veyer D; Combier A; Lafont E; Karras A; Mouthon L; Avouac J; Terrier B; Hadjadj J
    Clin Rheumatol; 2023 Sep; 42(9):2485-2490. PubMed ID: 37243801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-to-vaccine interval on SARS-CoV-2 immunogenicity in children: The potential role of prior natural infection.
    Gualtieri R; Yerly S; Garcia-Tarodo S; Parvex P; Rock N; Posfay-Barbe K; Didierlaurent AM; Eberhardt C; Blanchard-Rohner G
    Pediatr Allergy Immunol; 2024 May; 35(5):e14161. PubMed ID: 38796784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison and monitoring of antibody response in convalescent and healthy vaccinated individuals against RBD and PCS of SARS-CoV-2 spike protein.
    Mohammadzadeh Hosseini Moghri SAH; Ranjbar M; Hassannia H; Khakdan F
    J Biomol Struct Dyn; 2023; 41(23):14224-14231. PubMed ID: 36961201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral Response Following 3 Doses of mRNA COVID-19 Vaccines in Patients With Non-Dialysis-Dependent CKD: An Observational Study.
    Enilama O; Yau K; Er L; Atiquzzaman M; Oliver MJ; Romney MG; Leis JA; Abe KT; Qi F; Colwill K; Gingras AC; Hladunewich MA; Levin A
    Can J Kidney Health Dis; 2024; 11():20543581231224127. PubMed ID: 38292817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
    Abhishek A; Boyton RJ; Peckham N; McKnight Á; Coates LC; Bluett J; Barber V; Cureton L; Francis A; Appelbe D; Eldridge L; Julier P; Valdes AM; Brooks T; Rombach I; Altmann DM; Nguyen-Van-Tam JS; Williams HC; Cook JA;
    Lancet Respir Med; 2022 Sep; 10(9):840-850. PubMed ID: 35772416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study.
    Perkmann T; Mucher P; Perkmann-Nagele N; Radakovics A; Repl M; Koller T; Schmetterer KG; Bigenzahn JW; Leitner F; Jordakieva G; Wagner OF; Binder CJ; Haslacher H
    Microbiol Spectr; 2022 Feb; 10(1):e0140221. PubMed ID: 35196824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study.
    Kared H; Jyssum I; Alirezaylavasani A; Egner IM; The Tran T; Tietze L; Lund KP; Tveter AT; Provan SA; Ørbo H; Haavardsholm EA; Vaage JT; Jørgensen K; Syversen SW; Lund-Johansen F; Goll GL; Munthe LA
    Front Immunol; 2024; 15():1296273. PubMed ID: 38455062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study.
    Elmahdi R; Ward D; Ernst MT; Poulsen G; Hallas J; Pottegård A; Jess T
    BMJ Open; 2024 Feb; 14(2):e077408. PubMed ID: 38387988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial SARS-CoV-2 Antibody Titers in Vaccinated Dialysis Patients: Prevalence of Unrecognized Infection and Duration of Seroresponse.
    Hsu CM; Weiner DE; Manley HJ; Li NC; Miskulin D; Harford A; Sanders R; Ladik V; Frament J; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Kidney Med; 2023 Nov; 5(11):100718. PubMed ID: 37786901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural infection versus hybrid (natural and vaccination) humoral immune response to SARS-CoV-2: a comparative paired analysis.
    AbdelWareth L; Alhousani F; Abuyadek R; Donnelly J; Leinberger-Jabari A; Atef S; Al-Rifai RH
    Front Immunol; 2023; 14():1230974. PubMed ID: 37720219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.